Nalaganje...
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. The unique structure of CAR endows T cell tumor specific cytotoxicity and resistance to immunosuppressive microenvironment in c...
Shranjeno v:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3706354/ https://ncbi.nlm.nih.gov/pubmed/23829929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-47 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|